Assessment of tumor growth inhibition metrics to predict overall survival

Affiliations

Comment

L Claret et al. Clin Pharmacol Ther. 2014 Aug.

. 2014 Aug;96(2):135-7.

doi: 10.1038/clpt.2014.112.

¹ Pharsight Consulting Services, Pharsight, A Certara Company, Marseille, France.

No abstract available

Comment on

Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R. Claret L, et al. J Clin Oncol. 2013 Jun 10;31(17):2110-4. doi: 10.1200/JCO.2012.45.0973. Epub 2013 May 6. J Clin Oncol. 2013. PMID: 23650411
The use of model-based tumor-size metrics to predict survival.
Ribba B, Holford N, Mentré F. Ribba B, et al. Clin Pharmacol Ther. 2014 Aug;96(2):133-5. doi: 10.1038/clpt.2014.111. Clin Pharmacol Ther. 2014. PMID: 25056389 No abstract available.